Citadel Advisors
IBB icon

Citadel Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Citadel Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.4M Sell
91,500
-174,900
-66% -$29.9M ﹤0.01% 2655
2025
Q4 		$45M Buy
266,400
+32,500
+14% +$5.28M 0.01% 1523
2025
Q3 		$33.8M Buy
233,900
+142,600
+156% +$19.5M 0.01% 1753
2025
Q2 		$11.6M Sell
91,300
-103,800
-53% -$12.7M ﹤0.01% 2825
2025
Q1 		$25M Sell
195,100
-157,500
-45% -$21.4M ﹤0.01% 1789
2024
Q4 		$46.6M Sell
352,600
-257,000
-42% -$36.1M 0.01% 1332
2024
Q3 		$88.8M Sell
609,600
-294,900
-33% -$42.7M 0.02% 769
2024
Q2 		$124M Buy
904,500
+403,400
+81% +$53.9M 0.03% 570
2024
Q1 		$68.8M Sell
501,100
-223,700
-31% -$30.6M 0.01% 975
2023
Q4 		$98.5M Buy
724,800
+529,700
+272% +$64.6M 0.02% 689
2023
Q3 		$23.9M Sell
195,100
-144,000
-42% -$18.3M 0.01% 1682
2023
Q2 		$43.1M Sell
339,100
-356,400
-51% -$46.3M 0.01% 1169
2023
Q1 		$89.8M Sell
695,500
-112,300
-14% -$14.7M 0.02% 679
2022
Q4 		$106M Buy
807,800
+204,800
+34% +$26.5M 0.02% 624
2022
Q3 		$70.5M Buy
603,000
+263,200
+77% +$32.7M 0.02% 809
2022
Q2 		$40M Sell
339,800
-31,500
-8% -$3.74M 0.01% 1198
2022
Q1 		$48.4M Buy
371,300
+53,600
+17% +$6.98M 0.01% 1145
2021
Q4 		$48.5M Sell
317,700
-70,200
-18% -$10.9M 0.01% 1197
2021
Q3 		$62.7M Sell
387,900
-19,500
-5% -$3.28M 0.01% 959
2021
Q2 		$66.7M Sell
407,400
-123,600
-23% -$19M 0.01% 917
2021
Q1 		$79.9M Sell
531,000
-165,000
-24% -$26.2M 0.02% 713
2020
Q4 		$105M Sell
696,000
-353,200
-34% -$50.5M 0.03% 518
2020
Q3 		$142M Buy
1,049,200
+280,200
+36% +$38M 0.04% 299
2020
Q2 		$105M Sell
769,000
-24,900
-3% -$3.17M 0.04% 381
2020
Q1 		$85.5M Sell
793,900
-1,518,500
-66% -$175M 0.04% 400
2019
Q4 		$279M Buy
2,312,400
+1,370,400
+145% +$153M 0.12% 110
2019
Q3 		$93.7M Buy
942,000
+4,800
+0.5% +$502K 0.04% 431
2019
Q2 		$102M Buy
937,200
+140,100
+18% +$14.9M 0.05% 389
2019
Q1 		$89.1M Sell
797,100
-191,900
-19% -$21M 0.04% 409
2018
Q4 		$95.4M Buy
989,000
+43,000
+5% +$4.56M 0.05% 336
2018
Q3 		$115M Buy
946,000
+274,100
+41% +$32.3M 0.05% 361
2018
Q2 		$73.8M Buy
671,900
+209,500
+45% +$22.4M 0.04% 500
2018
Q1 		$49.4M Sell
462,400
-305,600
-40% -$33.9M 0.03% 610
2017
Q4 		$82M Sell
768,000
-210,000
-21% -$22.4M 0.05% 404
2017
Q3 		$109M Sell
978,000
-322,200
-25% -$34.4M 0.08% 227
2017
Q2 		$134M Buy
1,300,200
+211,200
+19% +$20.8M 0.11% 155
2017
Q1 		$106M Buy
1,089,000
+269,100
+33% +$25.8M 0.1% 187
2016
Q4 		$72.5M Sell
819,900
-112,200
-12% -$10.2M 0.07% 250
2016
Q3 		$89.9M Buy
+932,100
New +$88.7M 0.09% 192

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's IBB Position: Q1 2026 in Review

Citadel Advisors reduced its iShares Biotechnology ETF (IBB) stake by 80% in Q1 2026, selling an estimated $15.4M and leaving 22,005 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #4852.

Citadel Advisors first reported a position in IBB in Q2 2014 and has held it in 44 quarters since. The position peaked at $85.4M in Q2 2015. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Citadel Advisors held 22,005 shares of iShares Biotechnology ETF worth $3.72M as of Q1 2026.
  • Citadel Advisors sold 89,989 iShares Biotechnology ETF shares in Q1 2026, an estimated $15.4M.
  • iShares Biotechnology ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4852 holding.
  • Citadel Advisors first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 44 quarters since.
  • Citadel Advisors's iShares Biotechnology ETF position peaked at $85.4M in Q2 2015.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.